The small molecule glycoprotein IIb/IIIa inhibitor (GPI) eptifibatide is just as safe and effective as the better studied but more expensive abciximab in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). The less costly GPI’s noninferiority was confirmed by a small randomized trial as well as a large retrospective study, both of which appear in the August 3, 2010, issue of the Journal of the American College of Cardiology.

Reperfusion Equivalent in Randomized Trial

For the EVA-AMI (Eptifibatide Versus Abciximab in Primary PCI for Acute Myocardial Infarction) trial, researchers led by Uwe Zeymer, MD, of Herzzentrum Ludwigshafen ....

You must be a member to access this content. To continue reading, please enter your username and password above.

If you have not yet registered, we would like to take this opportunity to welcome you to TCTMD - The Source for Interventional Cardiovascular News & Education.

If you are already a member, please re-enter your username and password above, and then click LOGIN.

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.